| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: PDGM |
| Security Type |
Common Stock |
| Lead Underwriter |
Chase H&Q |
| Days In Registration |
77 |
| Date Filed |
18-Feb-2000 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Biotechnology company, focusing on the discovery and development of gene to cell biomarkers to reduce the cost, risk and time of product development, as well as to discover inaccessible targets for small-molecule discovery |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
24.96M |
| CEO and President |
John A. Ryals, Ph.D |
| Number of Employees |
118 |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
750.0K |
| File Amount |
- |
| File Price Range |
$16.00 - $14.00 |
| File Mid Price |
$15.00 |
Current Filing Information
(Amended 5-May-2000) |
|
US |
|
Shares Filed |
6.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
6.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$45.0M |
| · % Change from Original |
|
| File Price Range |
$8.00 - $7.00 |
| File Mid Price |
$7.50 |
|
